Press Releases August 20, 2026 05:00 PM

ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value as of July 2026

ArrowMark Financial Announces Estimated Net Asset Value for July 2026

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
BANX

ArrowMark Financial Corp., a non-diversified closed-end fund listed on NASDAQ under ticker BANX, disclosed its estimated and unaudited Net Asset Value (NAV) as of July 2026 to be $21.00. The company focuses on providing current income to shareholders through investments primarily in regulatory capital securities of financial institutions. The release includes disclaimers about investment risks and emphasizes that the estimated NAV is not a comprehensive financial statement.

ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value as of July 2026
BANX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Estimated NAV as of July 2026 is $21.00, indicating snapshot valuation.
  • ArrowMark Financial focuses on investments in regulatory capital securities of financial institutions, targeting income generation.
  • The company is a non-diversified closed-end fund listed on NASDAQ (BANX), managed by ArrowMark Asset Management, LLC.

DENVER, Aug. 20, 2026 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp., (NASDAQ: BANX) ("ArrowMark Financial"), today announced that BANX’s estimated and unaudited Net Asset Value (“NAV”) as of July 2026, 2026, was $21.00.

This estimated NAV is not a comprehensive statement of our financial condition or results for the month end.

About ArrowMark Financial Corp.
ArrowMark Financial Corp. is an SEC registered non-diversified, closed-end fund listed on the NASDAQ Global Select Market under the symbol “BANX.” Its investment objective is to provide shareholders with current income. BANX pursues its objective by investing primarily in regulatory capital securities of financial institutions. BANX is managed by ArrowMark Asset Management, LLC. To learn more, visit ir.arrowmarkfinancialcorp.com, or contact Destra at 877.855.3434 or by email at [email protected].

Disclaimer and Risk Factors:
There is no assurance that ArrowMark Financial will achieve its investment objective. ArrowMark Financial is subject to numerous risks, including investment and market risks, management risk, income and interest rate risks, banking industry risks, preferred stock risk, convertible securities risk, debt securities risk, liquidity risk, valuation risk, leverage risk, non-diversification risk, credit and counterparty risks, market at a discount from net asset value risk and market disruption risk. Shares of closed-end investment companies may trade above (a premium) or below (a discount) their net asset value. Shares of ArrowMark Financial may not be appropriate for all investors. Investors should review and consider carefully ArrowMark Financial's investment objective, risks, charges and expenses. Past performance does not guarantee future results.

The Annual Report, Semi-Annual Report and other regulatory filings of the Company with the SEC are accessible on the SEC's website at www.sec.gov and on the BANX’s website at ir.arrowmarkfinancialcorp.com.

Contact:
[email protected]


Risks

  • Investment and market risks inherent in financial securities, including interest rate and credit risks.
  • Liquidity and valuation risks, which may affect the fund's market price relative to NAV.
  • Market disruptions and potential for shares trading at discounts or premiums to NAV due to closed-end fund structure.

More from Press Releases

Inter&Co Delivers Record 3Q26 Net Income of US$76.1 Million, With Strong Growth, Higher Margin and Better Efficiency Nov 12, 2026 Super League to Report Third Quarter 2026 Financial Results on Monday, November 16, 2026 Nov 12, 2026 UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights Nov 4, 2026 BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules Nov 4, 2026 Jasper Therapeutics Announces 1-for-30 Reverse Stock Split Nov 4, 2026